血清学肿瘤标志物在肺癌诊断中的临床研究

目的 探讨糖类抗原(CA19-9)、癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA21-1)4种血清学肿瘤标志物在肺癌诊断中临床应用价值。方法 选取肺癌的患者60例、肺部良性病变组患者60例和健康体检者60例,三组研究对象均进行血清CA19-9、CEA、NSE、CYFRA21-1的检测。结果 CA19-9的阳性率在肺癌组、肺部良性病变组和健康体检组分别为46.67%、10%和3%,三组之间差异有统计学意义;CEA的阳性率在肺癌组、肺部良性病变组和健康体检组分别为58.33%、13.33%和3.33%,三组之间差异有统计学意义;NSE的阳性率在肺癌组、肺部良性病变组和健康体检组分别为50%、8.33%和1.67%,三组之间差异有统计学意义;CYFRA21-1的阳性率在肺癌组、肺部良性病变组和健康体检组分别为83.33%、15%和1.67%,三组之间差异有统计学意义;CA19-9、CEA、NSE和CYFRA21-1在肺癌诊断中灵敏度分别为46.67%、58.33%、50%和83.33%,特异度分别为93.33%、91.67%、95%和91.67%,四项血清学肿瘤标志物联合检测灵敏度是96.67%,特异度是88.33%。结论 肺癌相关血清学肿瘤指标的联合检测有助于提高肺癌诊断率,有必要深入探讨肺癌血清学肿瘤标志物在肺癌诊断中的联合检测,提高早期肺癌的诊断率。

The clinical research on the serum tumor markers in diagnosis of lung cancer

Objective To explore the clinical application value of CA19-9,CEA,NSE and CYFRA21-1 in the diagnosis of lung cancer.Methods 60 cases with lung cancer,60 cases with benign pulmonary disease and 60 healthy volunteers were chosen,then detected the serum tumor markers of CA19-9,CEA,NSE and CYFRA21-1.Results The positive rate of CA19-9 in lung cancer group,benign pulmonary disease group and healthy group were 46.67%,10% and 3%,respectively,and the difference was statistically significant; The positive rate of CEA in the three group were 58.33%,13.33% and 3.33%,respectively,and the difference was statistically significant; The positive rate of NSE in the three group were 50%,8.33% and 1.67%,respectively,and the difference was statistically significant; The positive rate of CYFRA21-1 in the three group were 83.33%,15% and 1.67%,respectively,and the difference was statistically significant; The sensitivity of CA19-9,CEA,NSE and CYFRA21-1 in the diagnosis of lung cancer were 46.67%,58.33%,50% and 83.33%,respectively,and the specificity were 93.33%,91.67%,95% and 91.67%,respectively.The sensitivity for of the four serum tumor marker was 96.67%,and the specificity was 88.33%.Conclusion The combined detection of serum tumor marker about lung cancer helps to increase the diagnosis rate of lung cancer,and it is necessary to further investigate the combined detection of serum tumor marker in the diagnosis of lung cancer,and improve the diagnostic rate of lung cancer in early stage.